Canadian Profiling and Targeted Agent Utilization Trial

Drug - Olaparib

300mg taken twice daily

Drug - Dasatinib

100mg administered orally once daily

Drug - Nivolumab plus Ipilimumab

Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

Drug - Axitinib

5mg orally twice daily

Drug - Bosutinib

500mg orally once daily

Drug - Crizotinib

250mg orally twice daily

Drug - Palbociclib

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

Drug - Sunitinib

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

Drug - Temsirolimus

25mg infused over a 30-60 minute period once a week

Drug - Erlotinib

150mg orally, once daily

Drug - Trastuzumab plus Pertuzumab

Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

Drug - Vemurafenib plus Cobimetinib

Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

Drug - Vismodegib

150mg taken orally, once daily